Orthotopic liver transplantation for polycystic liver disease with massive hepatomegaly

被引：0
作者：
Dreger, N. M. [1 ]
Kaiser, G. M. [1 ]
Treckmann, J. W. [1 ]
Mathe, Z. [1 ]
Benkoe, T. [1 ]
Paul, A. [1 ]
机构：
[1] Univ Klinikum Essen, Klin Allgemeinchirurg Viszeral & Transplantat Chi, D-45147 Essen, Germany
来源：
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2013年 / 138卷 / 47期
关键词：
polycystic liver disease; orthotopic liver transplantation; hepatomegaly; RANDOMIZED CONTROLLED-TRIAL; LONG-ACTING OCTREOTIDE; EVEROLIMUS; VOLUME; MODEL;
D O I：
10.1055/s-0033-1349654
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
History: A 51-year-old man (126kg, 192cm) with massive hepatomegaly causing cardiopulmonary symptoms was referred to our transplant center 14 years after initial diagnosis of polycystic liver disease. Treatment and course: Uneventful hepatectomy was followed by orthotopic liver transplantation using caval replacement. Donor liver came from a 73-year-old woman (extended criteria donor organ offer). A portocaval shunting was not established during transplantation although the explanted liver weighed 22kg. 18 months after transplantation liver function is stable and the patient enjoys normal quality of life. Conclusion: This case report demonstrates the value and success of transplantation for patients suffering from enormous hepatomegaly due to polycystic liver disease.
引用
收藏
页码：2407 / 2409
页数：3
相关论文
共 14 条
  • [1] Model for end-stage liver disease (MELD) exception for polycystic liver disease
    Arrazola, Luis
    Moonka, Dilip
    Gish, Robert G.
    Everson, Gregory T.
    [J]. LIVER TRANSPLANTATION, 2006, 12 (12) : S110 - S111
  • [2] Bundesarztekammer, RICHTL WART ORG LEB
  • [3] The long-term outcome of patients with polycystic liver disease treated with lanreotide
    Chrispijn, M.
    Nevens, F.
    Gevers, T. J. G.
    Vanslembrouck, R.
    van Oijen, M. G. H.
    Coudyzer, W.
    Hoffmann, A. L.
    Dekker, H. M.
    de Man, R. A.
    van Keimpema, L.
    Drenth, J. P. H.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (02) : 266 - 274
  • [4] Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: Results from a randomized controlled trial
    Chrispijn, Melissa
    Gevers, Tom J. G.
    Hol, Jeroen C.
    Monshouwer, Rene
    Dekker, Heleen M.
    Drenth, Joost P. H.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 59 (01) : 153 - 159
  • [5] Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial
    Chrispijn, Melissa
    Drenth, Joost P. H.
    [J]. TRIALS, 2011, 12
  • [6] Medical and Surgical Treatment Options for Polycystic Liver Disease
    Drenth, Joost P. H.
    Chrispijn, Melissa
    Nagorney, David M.
    Kamath, Patrick S.
    Torres, Vicente E.
    [J]. HEPATOLOGY, 2010, 52 (06) : 2223 - 2230
  • [7] Polycystic disease of the liver
    Everson, GT
    Taylor, MRG
    Doctor, RB
    [J]. HEPATOLOGY, 2004, 40 (04) : 774 - 782
  • [8] Diagnosis and management of polycystic liver disease
    Gevers, Tom J. G.
    Drenth, Joost P. H.
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2013, 10 (02) : 101 - 108
  • [9] Process of organ donation at a maximum care hospital
    Kaiser, G. M.
    Heuer, M.
    Stanjek, M.
    Schoch, B.
    Mueller, O.
    Waydhas, C.
    Mummer, P.
    Radunz, S.
    Wirges, U.
    Luetkes, P.
    Philipp, T.
    Schmid, K. W.
    Paul, A.
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2010, 135 (42) : 2065 - 2070
  • [10] KARHUNEN PJ, 1986, CLIN GENET, V30, P29
12